Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations.

Fischer MM, Yeung VP, Cattaruzza F, Hussein R, Yen WC, Murriel C, Evans JW, O'Young G, Brunner AL, Wang M, Cain J, Cancilla B, Kapoun A, Hoey T.

Sci Rep. 2017 Nov 10;7(1):15270. doi: 10.1038/s41598-017-15704-y.

2.

WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death.

Fischer MM, Cancilla B, Yeung VP, Cattaruzza F, Chartier C, Murriel CL, Cain J, Tam R, Cheng CY, Evans JW, O'Young G, Song X, Lewicki J, Kapoun AM, Gurney A, Yen WC, Hoey T.

Sci Adv. 2017 Jun 21;3(6):e1700090. doi: 10.1126/sciadv.1700090. eCollection 2017 Jun.

3.

Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer.

Lim JS, Ibaseta A, Fischer MM, Cancilla B, O'Young G, Cristea S, Luca VC, Yang D, Jahchan NS, Hamard C, Antoine M, Wislez M, Kong C, Cain J, Liu YW, Kapoun AM, Garcia KC, Hoey T, Murriel CL, Sage J.

Nature. 2017 May 18;545(7654):360-364. doi: 10.1038/nature22323. Epub 2017 May 10.

4.

Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types.

Chartier C, Raval J, Axelrod F, Bond C, Cain J, Dee-Hoskins C, Ma S, Fischer MM, Shah J, Wei J, Ji M, Lam A, Stroud M, Yen WC, Yeung P, Cancilla B, O'Young G, Wang M, Kapoun AM, Lewicki J, Hoey T, Gurney A.

Cancer Res. 2016 Feb 1;76(3):713-23. doi: 10.1158/0008-5472.CAN-15-0561. Epub 2015 Dec 30.

5.

Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency.

Yen WC, Fischer MM, Axelrod F, Bond C, Cain J, Cancilla B, Henner WR, Meisner R, Sato A, Shah J, Tang T, Wallace B, Wang M, Zhang C, Kapoun AM, Lewicki J, Gurney A, Hoey T.

Clin Cancer Res. 2015 May 1;21(9):2084-95. doi: 10.1158/1078-0432.CCR-14-2808.

6.

In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.

Bentzien F, Zuzow M, Heald N, Gibson A, Shi Y, Goon L, Yu P, Engst S, Zhang W, Huang D, Zhao L, Vysotskaia V, Chu F, Bautista R, Cancilla B, Lamb P, Joly AH, Yakes FM.

Thyroid. 2013 Dec;23(12):1569-77. doi: 10.1089/thy.2013.0137. Epub 2013 Sep 17.

7.

Discovery and characterization of an inhibitor of glucosylceramide synthase.

Richards S, Larson CJ, Koltun ES, Hanel A, Chan V, Nachtigall J, Harrison A, Aay N, Du H, Arcalas A, Galan A, Zhang J, Zhang W, Won KA, Tam D, Qian F, Wang T, Finn P, Ogilvie K, Rosen J, Aoyama R, Plonowski A, Cancilla B, Bentzien F, Yakes M, Mohan R, Lamb P, Nuss J, Kearney P.

J Med Chem. 2012 May 10;55(9):4322-35. doi: 10.1021/jm300122u. Epub 2012 Apr 19.

PMID:
22497444
8.

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.

Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH.

Mol Cancer Ther. 2011 Dec;10(12):2298-308. doi: 10.1158/1535-7163.MCT-11-0264. Epub 2011 Sep 16.

9.

A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

Eder JP, Shapiro GI, Appleman LJ, Zhu AX, Miles D, Keer H, Cancilla B, Chu F, Hitchcock-Bryan S, Sherman L, McCallum S, Heath EI, Boerner SA, LoRusso PM.

Clin Cancer Res. 2010 Jul 1;16(13):3507-16. doi: 10.1158/1078-0432.CCR-10-0574. Epub 2010 May 14.

10.

Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.

Gendreau SB, Ventura R, Keast P, Laird AD, Yakes FM, Zhang W, Bentzien F, Cancilla B, Lutman J, Chu F, Jackman L, Shi Y, Yu P, Wang J, Aftab DT, Jaeger CT, Meyer SM, De Costa A, Engell K, Chen J, Martini JF, Joly AH.

Clin Cancer Res. 2007 Jun 15;13(12):3713-23.

11.

Development of the zebrafish lymphatic system requires VEGFC signaling.

Küchler AM, Gjini E, Peterson-Maduro J, Cancilla B, Wolburg H, Schulte-Merker S.

Curr Biol. 2006 Jun 20;16(12):1244-8.

12.

Regulation of prostate branching morphogenesis by activin A and follistatin.

Cancilla B, Jarred RA, Wang H, Mellor SL, Cunha GR, Risbridger GP.

Dev Biol. 2001 Sep 1;237(1):145-58.

13.

Fibroblast growth factor receptors and their ligands in the adult rat kidney.

Cancilla B, Davies A, Cauchi JA, Risbridger GP, Bertram JF.

Kidney Int. 2001 Jul;60(1):147-55.

14.

Localization of activin beta(A)-, beta(B)-, and beta(C)-subunits in humanprostate and evidence for formation of new activin heterodimers of beta(C)-subunit.

Mellor SL, Cranfield M, Ries R, Pedersen J, Cancilla B, de Kretser D, Groome NP, Mason AJ, Risbridger GP.

J Clin Endocrinol Metab. 2000 Dec;85(12):4851-8.

PMID:
11134153
15.

Evidence that estrogens directly alter androgen-regulated prostate development.

Jarred RA, Cancilla B, Prins GS, Thayer KA, Cunha GR, Risbridger GP.

Endocrinology. 2000 Sep;141(9):3471-7.

PMID:
10965920
16.

Role of activins in the male reproductive tract.

Risbridger GP, Cancilla B.

Rev Reprod. 2000 May;5(2):99-104. Review.

PMID:
10864854
17.

Discrete cell- and stage-specific localisation of fibroblast growth factors and receptor expression during testis development.

Cancilla B, Davies A, Ford-Perriss M, Risbridger GP.

J Endocrinol. 2000 Feb;164(2):149-59.

PMID:
10657850
18.
19.

Differential localization of inhibin subunit proteins in the ovine testis during fetal gonadal development.

Jarred RA, Cancilla B, Richards M, Groome NP, McNatty KP, Risbridger GP.

Endocrinology. 1999 Feb;140(2):979-86.

PMID:
9927332
20.
21.

Light-microscopic immunolocalization of fibroblast growth factor-1 and -2 in adult rat kidney.

Cauchi J, Alcorn D, Cancilla B, Key B, Berka JL, Nurcombe V, Ryan GB, Bertram JF.

Cell Tissue Res. 1996 Aug;285(2):179-87.

PMID:
8766154

Supplemental Content

Loading ...
Support Center